Short Interest in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Increases By 58.9%

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 1,270,000 shares, an increase of 58.9% from the December 15th total of 799,400 shares. Based on an average daily volume of 171,900 shares, the days-to-cover ratio is presently 7.4 days. Currently, 7.4% of the company’s stock are short sold.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Barclays PLC boosted its position in shares of Telomir Pharmaceuticals by 325.1% during the third quarter. Barclays PLC now owns 7,018 shares of the company’s stock valued at $45,000 after buying an additional 5,367 shares during the last quarter. Beaird Harris Wealth Management LLC increased its holdings in Telomir Pharmaceuticals by 212.9% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after buying an additional 9,950 shares in the last quarter. State Street Corp raised its position in Telomir Pharmaceuticals by 99.1% in the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after buying an additional 17,967 shares during the last quarter. Suncoast Equity Management lifted its stake in Telomir Pharmaceuticals by 109.9% during the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock valued at $329,000 after acquiring an additional 26,803 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter valued at about $241,000.

Telomir Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ TELO traded down $0.05 during midday trading on Thursday, hitting $4.79. The stock had a trading volume of 78,095 shares, compared to its average volume of 125,643. Telomir Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $20.72. The business’s 50 day moving average is $4.59 and its 200-day moving average is $4.75.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.